CoChat

Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants

Open access

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

BACKGROUND: Recent experimental and epidemiological studies have suggested that osteoprotegerin, a key regulator in bone metabolism, may be involved in vascular calcification and atherosclerosis. Our aim was to reliably quantify the associations of osteoprotegerin concentration and incidence of first-ever cardiovascular disease outcomes in the general population. METHODS: Using the electronic databases MEDLINE, EMBASE and Web of Science (January 1975 and April 2017, no language restrictions), nine relevant studies were identified involving a total of 26,442 participants recruited from the general population. Over a mean follow-up of 8.5 years, 2,160 cardiovascular disease, 2,123 coronary heart disease, and 1,102 stroke outcomes were recorded. Study-specific risk ratios were combined with random-effects meta-analysis. RESULTS: When comparing individuals in the top with those in the bottom third of osteoprotegerin concentration, the combined risk ratio was 1.83 (95% confidence interval: 1.46, 2.30; P<0.001; I2 = 76.8%) for cardiovascular disease, 1.72 for coronary heart disease (1.26, 2.37; P = 0.001; I2 = 83.5%), and 1.58 for stroke (1.18, 2.12; P = 0.002; I2 = 65.2%). Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease). Magnitudes of associations did not differ according to the proportion of males, geographical region, or osteoprotegerin assay manufacturer. There was no evidence for publication bias for any of the outcomes assessed (all P>0.05). CONCLUSIONS: Elevated osteoprotegerin concentration is associated with an increased risk of incident cardiovascular disease in the general population. The mechanisms underlying this observation deserve further investigation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0183910

Cites

Statistics

Figures

Fig 1 PRISMA flow diagram. aWe identified 823 records in Pubmed, 728 in Web of Science, and 1052 in EMBASE.
Fig 1 PRISMA flow diagram. aWe identified 823 records in Pubmed, 728 in Web of Science, and 1052 in EMBASE.CC BY · PubMed Central
Fig 2 Combined relative risk for cardiovascular outcomes in the top vs. the bottom third of OPG concentration. CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; OPG = osteoprotegerin. Full study names are listed in the footnote of Table 2. Sizes of data markers indicate the weight of each study in the analysis. Study-specific relative risks were pooled using random-effects meta-analysis.
Fig 2 Combined relative risk for cardiovascular outcomes in the top vs. the bottom third of OPG concentration. CHD = coronary heart disease; CI = confidence interval; CVD = cardiovascular disease; OPG = osteoprotegerin. Full study names are listed in the footnote of Table 2. Sizes of data markers indicate the weight of each study in the analysis. Study-specific relative risks were pooled using random-effects meta-analysis.CC BY · PubMed Central
Fig 3 Funnel plots of reported associations between osteoprotegerin and risk of cardiovascular outcomes. Full study names are listed in the footnote of Table 2. The dotted lines show pseudo 95% confidence intervals around the overall pooled estimate. P values are from Egger’s asymmetry test of associations.
Fig 3 Funnel plots of reported associations between osteoprotegerin and risk of cardiovascular outcomes. Full study names are listed in the footnote of Table 2. The dotted lines show pseudo 95% confidence intervals around the overall pooled estimate. P values are from Egger’s asymmetry test of associations.CC BY · PubMed Central
Fig 4 Relative risks for cardiovascular outcomes in the top vs bottom third of osteoprotegerin concentration according to average age and proportion of males in contributing studies. P values were derived from meta-regression. The marker size is proportionate to the inverse variance of the study-specific relative risk.
Fig 4 Relative risks for cardiovascular outcomes in the top vs bottom third of osteoprotegerin concentration according to average age and proportion of males in contributing studies. P values were derived from meta-regression. The marker size is proportionate to the inverse variance of the study-specific relative risk.CC BY · PubMed Central
Fig 5 Relative risks for cardiovascular outcomes in the top vs bottom third of osteoprotegerin concentration according to categories of study characteristics. aP values were derived from meta-regression. Levels of adjustment: o, unadjusted; +, adjusted for age and sex; ++, additionally adjusted for at least one non-blood based risk factor and one blood-based risk factor.
Fig 5 Relative risks for cardiovascular outcomes in the top vs bottom third of osteoprotegerin concentration according to categories of study characteristics. aP values were derived from meta-regression. Levels of adjustment: o, unadjusted; +, adjusted for age and sex; ++, additionally adjusted for at least one non-blood based risk factor and one blood-based risk factor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 53 · Cited by 45

Metadata

Authors
Tschiderer, L., Willeit, J., Schett, G., Kiechl, S., & Willeit, P.
Affiliations
  • Innsbruck Medical University (AT)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Corresponding author
Willeit, Peter
Venue
PLOS ONE
Published
2017-08-24
Volume
12
Issue
8
Pages
e0183910
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2746047252
Cited by
45
References
53
Citations by year
2026: 1 · 2025: 3 · 2024: 9 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 1 · 2019: 8 · 2018: 5
FWCI
4.20
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
Funders
Austrian Research Promotion Agency FFG (843536)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Keywords
osteoprotegerin, cardiovascular risk, coronary artery disease, stroke, vascular calcification, atherosclerosis, bone metabolism, plasma biomarkers, general population
MeSH terms
Cardiovascular Diseases, Humans, Risk Factors, Incidence, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. https://app.cochat.ai/papers/10.1371/journal.pone.0183910
The paper
Tschiderer, L., Willeit, J., Schett, G., Kiechl, S., & Willeit, P. (2017). Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLOS ONE. https://doi.org/10.1371/journal.pone.0183910

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.